|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 906.5 USD | -0.09% |
|
+0.59% | +3.22% |
By Josh Beckerman
Regeneron Pharmaceuticals Inc.'s Covid-19 antibody cocktail has received an expanded Emergency Use Authorization from the Food and Drug Administration.
The expanded authorization enables use of REGEN-COV for post-exposure prophylaxis in certain people exposed to a SARS-CoV-2 infected individual, or who are at high risk of exposure to an infected person in an institutional setting.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
07-30-21 1413ET
| 1st Jan change | Capi. | |
|---|---|---|
| +3.22% | 97.5B | |
| -1.51% | 105B | |
| +1.86% | 22.19B | |
| -16.53% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.09% | 14.52B | |
| +5.47% | 14.09B | |
| +28.85% | 10.99B | |
| -24.93% | 8.63B |
REGENERON PHARMACEUTICALS, INC. 
